SCHEMBL27201488

SCHEMBL27201488

O=C(O)N1CCC=C(c2ccccc2Br)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.36
ALDH1A1 P00352 5/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 3/20 0.34
CARM1 Q86X55 3/20 0.33
EP300 Q09472 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 3/20 0.33
ALOX15 P16050 1/20 0.33
XIAP P98170 1/20 0.33
HKDC1 Q2TB90 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RECQL P46063 1/20 0.33
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27791722 0.82 CCNT1 (0.39) LMNAKDM4ESMN1; SMN2TSHRALOX15
SCHEMBL27201656 0.80 PDK4 (0.47) MAPK1
SCHEMBL15140927 0.79 ALDH1A1 (0.42) ALDH1A1MAPK1SMN1; SMN2TSHRALOX15
SCHEMBL30834261 0.76 LMNA (0.40) ALDH1A1LMNAKDM4ESMN1; SMN2TSHR
SCHEMBL28750123 0.76 ALDH1A1 (0.47) KIF11ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL29145758 0.74 KMT2A (0.34) L3MBTL1HPGD
SCHEMBL27201600 0.73 KDM4E (0.47) ALDH1A1LMNAKDM4EALOX15HSD17B10
SCHEMBL25168915 0.72 GOT1 (0.43) RECQLMAPT
SCHEMBL28460453 0.71 LMNA (0.31) LMNA
SCHEMBL30824542 0.71 RAB9A (0.41) ALDH1A1KDM4ESMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP KIF11 2879/4885ALDH1A1 1247/4885LMNA 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.